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Abstract 
PrimPol is a DNA damage tolerance enzyme possessing both translesion 
synthesis (TLS) and primase activities. To uncover its potential role in 
TLS-mediated IgVλ hypermutation and define its interplay with other TLS 
polymerases, PrimPol-/- and PrimPol-/-/Polη-/-/Polζ -/- gene knockouts were 
generated in avian cells. Loss of PrimPol had no significant impact on the rate of 
hypermutation or the mutation spectrum of IgVλ. However, PrimPol-/- cells were 
sensitive to methylmethane sulfonate, suggesting that it may bypass abasic 
sites at the IgVλ segment by repriming DNA synthesis downstream of these sites. 
PrimPol-/- cells were also sensitive to cisplatin and hydroxyurea, indicating that it 
assists in maintaining / restarting replication at a variety of lesions. To accurately 
measure the relative contribution of the TLS and primase activities, we examined 
DNA damage sensitivity in PrimPol-/- cells complemented with polymerase or 
primase-deficient PrimPol. Polymerase-deficient, but not primase-deficient, 
PrimPol suppresses the hypersensitivity of PrimPol-/- cells. This indicates that its 
primase, rather than TLS activity, is pivotal for DNA damage tolerance. Loss of 
TLS polymerases, Polη and Polζ has an additive effect on the sensitivity of 
PrimPol-/- cells. Moreover, we found that PrimPol and Polη-Polζ redundantly 
prevented cell death and facilitated unperturbed cell cycle progression. PrimPol-/- 
cells also exhibited increased sensitivity to a wide variety of chain-terminating 
nucleoside analogs (CTNAs). PrimPol could perform close-coupled repriming 
downstream of CTNAs and oxidative damage in vitro. Together, these results 
indicate that PrimPolʼs repriming activity plays a central role in reinitiating 
replication downstream from CTNAs and other specific DNA lesions. 
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Introduction 
Genome replication is stalled by DNA secondary structures and unrepaired 
damage, potentially leading to fork collapse, mutagenesis, and genome 
instability.1 Eukaryotic cells have evolved several mechanisms to complete 
replication beyond a damaged template. The first is translesion DNA synthesis 
(TLS), which employs specialized DNA polymerases, including Polymerase η 
and Polymerase ζ, to permit continued replication beyond the damaged 
template.2-5 A second mechanism is homologous recombination (HR), which 
mediates continuous replication using a newly synthesized sister strand.6-8 A 
third mechanism, in which DNA primases play a role, involves the repriming of 
DNA synthesis downstream from the lesion or structure.9-13  
 
Primase-Polymerase (PrimPol) is a member of the archaeo-eukaryotic primase 
(AEP) superfamily,14 was recently identified as a novel primase-polymerase that 
possesses both TLS polymerase and primase activities that are involved in DNA 
damage tolerance in eukaryotic organisms.15-18 PrimPol has two functional 
domains: an archaeo-eukaryotic primase (AEP) polymerase domain and a 
DNA-binding, zinc-finger domain.13 The AEP polymerase domain is required for 
both catalytic activities, while the zinc-finger domain is required only for primase 
activity,13 with a potential additional role in modulating polymerase fidelity and 
processivity to limit misincorporation during DNA synthesis. PrimPolʼs capacity 
to reprime appears to be important for maintaining replication fork progression at 
sites of UV damage12, 13 and at structured DNA, such as G quadruplexes.19 
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Deletion of PrimPol in avian DT40 cells leads to replication fork slowing, damage 
sensitivity and a pronounced G2/M checkpoint arrest after UV irradiation.20 
Deletion of a PrimPol orthologue PPL2 in trypanosomes is lethal.17 PrimPol is a 
very unprocessive enzyme with low fidelity and a mutation spectrum that is 
highly biased towards insertion-deletion errors. 21 The activity of PrimPol 
appears to be modulated by its binding to single-stranded binding proteins.  
 
A point mutation (tyrosine 89 to aspartic acid) located in the AEP polymerase 
domain of PrimPol has been identified in familial high myopia.22 The PrimPolY89D 
mutant enzyme is primase-active, but exhibits significantly reduced DNA 
polymerase activity.23 Mutation or deletion of the zinc-finger domain 
(PrimPolZF-KO and PrimPol1-354, respectively) in PrimPol leads to loss of primase 
activity but does not diminish primer extension synthesis, indicating that the 
zinc-finger domain plays a key role in the primase activity.13 
 
Recent studies have shown that PrimPolʼs enzymatic properties, including its 
ability to initiate new DNA synthesis beyond several types of replicase stalling 
lesions and structures, help to maintain active replication.12, 15, 16 One current 
model of cellular TLS postulates that after replicative polymerases have halted at 
lesions, the stalled forks are restarted by specialized DNA polymerases, 
including Polη and Polζ, which are capable of TLS. 4, 24 The active sites of these 
enzymes are less spatially constrained than replicative polymerases and can 
thus accommodate distorted base-pairing involving damaged bases.25, 26 
Eukaryotic cells have evolved a number of TLS polymerases with distinctive 
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bypass activities, though the division of labour among these various enzymes 
has not yet been fully elucidated. Likewise, although it is believed that PrimPol 
contributes to the cellular tolerance of DNA damage by facilitating damage 
bypass, the relationship between PrimPol and other TLS polymerases remains 
to be defined. 
 
To better define the roles played by PrimPol in damage tolerance, we generated 
PrimPol-/- and PrimPol-/-/Polη-/-/Polζ -/- cells derived from the chicken DT40 B cell 
line. DT40 cells undergo TLS mediated IgVλ hypermutation during in vitro 
passage. Thus, the unique advantage of this cell line for the phenotypic analysis 
of TLS is that the DNA sequence analysis of IgVλ allows identification of 
nucleotides inserted opposite abasic sites by TLS. We show that the loss of 
PrimPol has no significant impact on the rate of hypermutation and mutation 
spectrum of IgVλ. However, PrimPol-/- cells were sensitive to methylmethane 
sulfonate (MMS), which generates abasic sites. These data suggest that 
PrimPol may bypass abasic sites at the IgVλ segment by repriming DNA 
synthesis downstream of the abasic sites. Consistently, the expression of a 
polymerase-deficient PrimPol in PrimPol-/- cells significantly suppressed this 
hypersensitivity, while the expression of primase-deficient PrimPol exhibited little 
suppression. Notably, PrimPol-/-/Polη-/-/Polζ -/- cells proliferated very slowly and 
exhibited increased cell death, although both PrimPol -/- and Polη-/-/Polζ -/- cells 
were able to proliferate with nearly normal kinetics. These results suggest that 
repriming by PrimPol and TLS by Polη and Polζ are compensatory for each other 
for facilitating physiological levels of DNA replication. Additionally, we found 
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strong sensitivity of PrimPol-/- cells to chain-terminating nucleoside analogs 
(CTNAs). Finally, we demonstrate that PrimPol is able to perform close-coupled 
repriming downstream of CTNAs and DNA damage lesions. Taken together, 
these data suggest novel roles for the primase activity of PrimPol in repriming 
DNA synthesis downstream of CTNAs incorporated on the primer strand that 
block 3ʼ extension by the replicative polymerases. 
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Results 
DT40 cells lacking PrimPol are viable  
In order to study the possible roles of PrimPol in TLS-dependent IgV 
hypermutation, we disrupted the PrimPol gene 15 in Cl18, a subclone of DT40.27 
This subclone has been used for analyzing HR mediated gene conversion and 
TLS-dependent hypermutation event in immunoglobulin Vλ (IgVλ) segment, 
because this cell line has uniform IgVλ sequence and change of sequence can 
be easily assessed by sequencing analysis.2, 3, 5 To disrupt the chicken PrimPol 
locus, we constructed two targeting vectors, PrimPol-bsr and PrimPol-pur (Fig. 
S1A) and sequentially transfected these constructs into wild-type DT40 cells. 
Targeted disruption on the PrimPol gene was verified by Southern blot analysis 
of EcoT22I-digested genomic DNA with the use of an internal 5ʼ probe (Fig. S1B) 
and RT-PCR (Fig. S1C). The PrimPol -/- cells proliferated with normal kinetics 
(Fig. S1D) but showed a slightly increased G2 population as previously reported 
(Fig. S1E).15, 20 
 
PrimPol-/- cells are hypersensitive to UV, MMS and cisplatin 
Previously, we reported that PrimPol-/- cells exhibit UV sensitivity, but not ionizing 
radiation.15 To understand roles played by PrimPol more comprehensively, we 
measured sensitivity to a wider range of exogenous DNA damaging agents 
(cisplatin, HU, MMS, ICRF193 and camptothecin). PrimPol-/- cells were not 
sensitive to ICRF193, camptothecin or γ-rays, confirming that PrimPol is not vital 
for strand break repair. 15 Survival assays revealed that PrimPol-/- cells were 
more sensitive to ultraviolet (UV), methylmethane sulfonate (MMS), cisplatin and 
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hydroxyurea (HU) treatments than wild-type cells (Fig. 1). These data suggest 
that PrimPol plays roles in the restart of replication at sites of DNA damage. 
Hypersensitivity to a wide range of DNA replication blocking agents is also 
observed in RAD18-/-, Polζ-/- and PCNA K164R /K164R cells, 2, 28, 29 suggesting that 
lesion bypass is significantly impaired in PrimPol-/- cells. 
 
PrimPol plays roles in damage tolerance independently of Polη and Polζ 
Notably, we found that PrimPol-/-/Polη-/-/Polζ-/- cells proliferated more slowly than 
wild-type, PrimPol-/- or Polη-/-/Polζ-/- cells (Fig. 2A). Moreover, 
PrimPol-/-/Polη-/-/Polζ-/- cells exhibited significantly higher levels of spontaneous 
cell death than observed with wild-type, PrimPol-/- 20 or Polη-/-/Polζ-/- cells as 
evidenced by the observations that sub-G1 (dead cells) fraction in the cell cycle 
distribution was increased in PrimPol-/-/Polη-/-/Polζ-/- cells (Fig. 2B-C). In addition, 
PrimPol-/-/Polη-/-/Polζ-/- cells tended to exhibit more prominent G2 arrest after 
exposure to cisplatin than wild-type, PrimPol-/- or Polη-/-/Polζ-/- cells (Fig. 2B-C). 
These results suggest that the repair kinetics of the DNA damage is critically 
reduced in PrimPol-/-/Polη-/-/Polζ-/- cells. Furthermore, the loss of Polη and Polζ 
increased sensitivity to DNA damage in PrimPol-/- cells to the same extent as in 
the wild-type cells and, critically, the triple mutant was much more sensitive (Fig. 
2D). These observations indicate that PrimPol and Polη-Polζ-dependent TLS 
contribute to DNA-damage tolerance independently of each other.  
 
PrimPol is dispensable for IgVλ hypermutation 
To analyze the rolen of PrimPol in TLS in vivo, we analyzed the diversification of 
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the IgVλ region, since its non-templated hypermutation at the C/G pair (hereafter 
called hypermutation) is caused by TLS past abasic sites.3, 5, 30-32 DT40 cells 
constitutively diversify their IgVλ locus by hypermutation and by gene conversion 
from pseudo-Vλ segments to the downstream VJλ segment through HR. 
Therefore, phenotypic analysis of IgVλ diversification during in vitro passage 
provides a novel opportunity to functionally analyze the two alternative 
mechanisms of releasing replication blockage: TLS and HR33 (Fig. S2). Indeed, 
the rate of TLS dependent IgVλ hypermutation was critically reduced in TLS 
defective PCNAK164R, RAD18-/-, POLD3-/- and Polη-/-/Polν-/-/Polθ-/- cells 5, 3, 29. 
Notably, the rates of hypermutation and gene-conversion events were similar 
between PrimPol-/- and wild-type cells (Fig. 3A-B). Moreover, the mutation 
spectrum was not significantly changed by the loss of PrimPol in wild-type and 
Polη-/-/Polζ-/- cells (Fig. 3C). Notably, PrimPol-/-/Polη-/-/Polζ-/- cells exhibited only 
slightly reduced hypermutation levels, demonstrating that TLS is active in the 
triple mutant (Fig. 3). Taken together, these results indicate that PrimPol is 
dispensable for TLS dependent IgVλ hypermutation. Considering the serious 
proliferation defect, as well as the increased sensitivity to damage in the triple 
mutant, PrimPol might play a critical role in damage tolerance independently of 
TLS and this role compensates for the TLS defects in Polη-/-/Polζ-/- cells. 
 
PrimPolʼs repriming activity is required to tolerate replication-stalling 
lesions 
To test whether PrimPolʼs repriming activity also contributes to tolerance of other 
replication-stalling lesions, other than UV (currently Ref 18), we expressed 
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PrimPolY89D (reduced TLS, primase active), PrimPolZF-KO (TLS active, primase 
defective), and PrimPol1-354 (TLS active, primase defective) in PrimPol-/- cells (Fig. 
4A-B). PrimPolY89D complemented the reduced damage tolerance of PrimPol-/- 
cells, as did wild-type PrimPol (Fig. 4C). This result is consistent with our 
previous observation that PrimPolY89D complements increased fork arrest in 
PrimPol-/- cells treated with UV light to the same degree as does wild-type 
PrimPol 23. In contrast, neither PrimPolZF-KO nor PrimPol1-354 suppressed 
hypersensitivity to MMS, UV, or cisplatin in PrimPol-/- cells, indicating that the 
repriming activity of PrimPol, rather than its TLS activity, is pivotal for cellular 
tolerance to these replication stalling lesions (Fig. 4C). Consistently, the number 
of chromosome aberrations induced by cisplatin was increased in PrimPol-/- cells, 
PrimPol-/-+PrimPol1-354 and PrimPol-/-+PrimPolZF-KO cells, but not in 
PrimPol-/-+PrimPolY89D cells (Fig. 4D). Moreover, expression of PrimPolY89D but 
not PrimPolZF-KO or PrimPol1-354 rescued hypersensitivity to cisplatin in 
PrimPol-/-/Polη-/-/Polζ-/- cells (Fig. 4E), indicating that this suppression is 
independent of Polη and Polζ. Together, these findings suggest that 
PrimPol-mediated repriming of replication plays a critical role in cellular tolerance 
to a variety of replication stalling lesions and serves as a critical alternative 
pathway to complement for the potential loss of Polη-Polζ mediated TLS. 
 
PrimPolʼs primase activity is required for cellular tolerance of chain 
terminating nucleotide analogues (CTNA) 
Given the critical requirement of the primase activity of PrimPol for cellular 
tolerance to replication stalling lesions, we next analyzed the role of this activity 
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in cellular tolerance to CTNAs. CTNAs cause replicase stalling by preventing 
polymerases from incorporating further nucleotides when CTNAs are added at 
the 3ʼ-temini of growing DNA polymers.34, 35 PrimPol-/- cells exhibited more 
sensitivity to a wide range of CTNAs including Abacavir (ABC) 36-38, Zidovudine 
(AZT) 39 and acyclovir 40 than observed with wild-type cells (Fig. 5A). Moreover, 
PrimPolY89D complemented the reduced CTNA tolerance of PrimPol-/- cells, while 
neither PrimPolZF-KO nor PrimPol1-354 suppressed the increased sensitivity, 
indicating that the primase activity of PrimPol rather than the TLS activity is 
pivotal for cellular tolerance to replication stalling induced by incorporation of 
CTNAs (Fig. 5B).  
 
PrimPol reprimes replication downstream of CTNA incorporated sites and 
DNA damage lesions in vitro 
Given the critical role of PrimPol in the cellular tolerance to CTNAs and the 
apparent requirement of the enzymeʼs primase activity for this tolerance, we next 
tested PrimPolʼs capacity to reprime downstream of the 3ʼ side of an 
incorporated CTNA. Since the ABC drug is phosphorylated in a unique stepwise 
anabolism to be converted to the triphosphated guanine analog, carbovir, in cells, 
41 we assessed repriming downstream of carbovir, in addition to acyclovir, in 
vitro. In order to analyze repriming downstream of a CTNA incorporation site, a 
primer containing CTNA (carbovir or acyclovir) at its terminal 3ʼ end was 
annealed to a biotinylated DNA template. In addition, we analyzed the ability of 
PrimPol to reprime downstream of an apurinic/apyrimidinic site (Ap site) and 
thymine glycol (Tg) lesion located in the template strand, both of which PrimPol 
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is unable to bypass through TLS in the presence of magnesium.13  In this case, 
a 3ʼ dideoxynucleotide primer was annealed upstream of the templating lesion to 
represent a situation where replication has stalled at the damage site. The 3ʼ 
dideoxy moiety also prevents template-independent primer extension that 
interferes with the evaluation of PrimPolʼs repriming activity. 
  
Although PrimPol is unable to synthesize through the lesions or extend from 3ʼ 
terminal CTNAs, the enzyme displayed a capacity to perform close-coupled de 
novo synthesis of primer strands downstream in each case (Fig. 6). The size of 
the extended products, both with 3ʼ carbovir and 3ʼ acyclovir primers, in addition 
to the templating Ap site and Tg lesion, were consistent with repriming ~14 nt 
downstream of the CTNAs or lesion site. Importantly, in the absence of the 
CTNA primer or lesion, PrimPol generated longer and more variable synthesis 
products, indicating that PrimPol is performing close-coupled repriming 
downstream of a stalled replication fork. Taken together, these results indicate 
that repriming by PrimPol downstream of an incorporated CTNA or damage site 
is a potentially important mechanism for maintaining replication in the presence 
of these potentially lethal chain terminators and DNA lesions.  
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Discussion 
In this study, we provide further evidence that PrimPolʼs primase activity, rather 
than its TLS activity, is required for cellular tolerance to a variety of replication 
blocking lesions. We also show that although PrimPol is required to maintain 
replication fork progression at sites of UV-damage,13, 15, 16 we could not detect 
any gross defect in IgVλ mutagenesis, which is dependent on TLS bypass of 
abasic sites. Since abasic sites are the most common spontaneously arising 
lesions in chromosomal DNA,42 it is possible that cells have evolved multiple 
polymerases to continue replication beyond these abundant DNA lesions and 
any effects due to loss of the PrimPol in IgVλ mutagenesis were masked. 
Another possibility is that PrimPol facilitates continuous replication beyond 
lesions via de novo repriming of replication downstream from the damage. In 
accordance with this hypothesis, expression of mutant PrimPol enzyme 
(PrimPolY89D) possessing reduced TLS activity facilitates the restart of fork arrest 
at UV lesions in PrimPol-/- cells, whilst mutant PrimPol enzymes (PrimPolZF-KO or 
PrimPol1-354) defective in primase activity do not correct the fork-progression 
defect observed in UV-treated PrimPol-/- cells.13, 23 We recently reported that 
close-coupled repriming by PrimPol is required for replicative tolerance of G 
quadruplexes in verterbrate cells.19 Complementary to these findings, we show 
here that PrimPol displays a capacity to perform close-coupled repriming 
downstream of other potential replication fork stalling DNA damage lesions in 
vitro. Since PrimPol is able to extend RNA primers with ribonucleotides, even 
when bypassing 8oxoG lesions,43 it is possible that TLS by PrimPol also assists 
transcription at damaged template.  
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A point mutation in PrimPol found in familial high myopia (Y89D) is located in the 
conserved AEP domain. 22 The link between this mutation and high myopia has 
been a matter of debate.44, 45 This mutant enzyme exhibits reduced polymerase 
processivity.13, 23 Consistently, cells expressing PrimPolY89D exhibit reduced 
fork-progression rates.13, 23 However, we did not detect any gross defect in 
chromosome stability or replication-block tolerance (Fig. 4). It is possible that the 
over-expression of PrimPolY89D in our assay system masked the effect of 
reduced polymerase activity in this mutant enzyme. Another possibility is that 
multiple polymerases, including TLS polymerases and replicative polymerases, 
compensate for the reduced polymerase activity of PrimPol. Recent studies 
consistently show a redundancy in the way multiple TLS polymerases are 
working, and that even replicative polymerase δ compensates for the loss of TLS 
polymerase.2, 3, 5 
 
How the appropriate damage tolerance polymerase is chosen from among the 
multiple stalled-fork recovery systems is largely unknown. The similar levels of 
hypersensitivity to DNA damaging agents found in PrimPol-/- and PrimPol-/- + 
PrimPol (ZF-KO) cells, in addition to the ability of PrimPol to reprime 
downstream of DNA damage lesions in vitro, has led us to hypothesize that 
repriming of replication downstream from a DNA lesion might play a more 
important role in the recovery of stalled forks than previously thought.46, 47 The 
simultaneous loss of Polη and Polζ caused no significant decrease in 
TLS-dependent IgVλ hypermutation but a significant change in the mutation 
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pattern,2 suggesting that other polymerases carry out TLS in their absence. 
Moreover, the loss of PrimPol in Polη-/-/Polζ-/- cells did not significantly further 
reduce TLS-dependent IgVλ hypermutation. Thus, the contribution of PrimPol to 
TLS-dependent IgVλ hypermutation, even in the absence of Polη and Polζ, might 
be limited, if it exists at all. In contrast, PrimPol-/- /Polη-/-/Polζ-/- cells exhibited 
critical defects in cellular proliferation and tolerance to DNA damaging agents, 
suggesting that PrimPol serves as a critical backup for Polη and Polζ in 
stalled-fork recovery. Thus, PrimPol-dependent repriming of replication might 
provide a redundant mechanism to facilitate fork recovery by TLS. How repriming 
of DNA replication is regulated is therefore an important issue to be investigated 
in future studies. 
 
In this study, we also identified a critical role for repriming by PrimPol in the 
cellular tolerance of CTNAs. Anti-viral CTNAs can lead to strong mitochondrial 
toxicity due to their incorporation by the less selective mitochondrial Polγ.48 Our 
findings suggest that repriming by PrimPol might be critical for the completion of 
DNA replication against CTNAs in both mitochondrial and nuclear replication. 
The use of chain-terminating nucleoside analogs, in combination with other 
chemotherapeutic treatments, to kill cancer cells shown to have mutated or low 
expression levels of PrimPol might be a promising chemotherapy strategy. 
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Material and Methods 
Disruption of PrimPol in chicken DT40 cells 
DT40 cells were provided by the Takeda lab.27 PrimPol disruption constructs 
were generated from genomic PCR products combined with puroR and bsrR 
selection-marker cassettes. Genomic DNA sequences were amplified using 
primers  
5ʼ- CAGTCCAGTAATAAAGAAGGAATCACTTAC-3ʼ and 5ʼ- 
CCCATTTTCTCTTCATTTGTCCTAAAGCAA -3ʼ for the 5ʼ arm of the targeting 
construct and 5ʼ- TCAGGAGTCACCGTATCCAGAGATTGATT -3ʼ and 5ʼ- 
ATACAGTATTTGGCTTATCAGTAGAAGTTG -3ʼ for the 3ʼ arm. PCR was 
conducted using PrimeStar GXL DNA polymerase (Takara Bio) according to the 
manufacturer's instructions. An amplified 1.6 kb 3ʼ arm and a 1.7 kb 5ʼ arm were 
cloned into the XbaI-BamHI and BamHI -SalI sites, respectively, of a pBlueScript 
SK vector. Marker-gene cassettes, puroR and bsrR selection-marker genes, 
flanked by loxP sequences, were inserted into the BamHI site to generate 
PrimPol-puroR and PrimPol -bsrR. To generate PrimPol -/- cells, wild-type DT40 
cells were transfected sequentially with PrimPol-puroR and PrimPol -bsrR. A PCR 
fragment produced from genomic DNA using primers 
5ʼ-ATTCTGCTGAATCAAAACCACCACACAC-3ʼ and  
5ʼ- TCAGCTTCCTGTTTAGATCAGTATGCTC -3ʼ was used as a probe for 
Southern blot analysis to screen gene-targeting events. 
 
RT-PCR 
The lack of functional PrimPol was confirmed by RT-PCR using primers 5ʼ- 
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CGACAGGCTGATGCTTTCAGATTTGTG-3ʼ	 and   
5ʼ- CCTTTGGAAGCATCTTCGACTGCTGTG -3ʼ. β-actin transcripts were 
analyzed using primers  
5 ʼ-AAAATCAAGATCATTGCCCCACCTGAG-3 ʼ  and  
5 ʼ- CCTTCATTCACATCTATCACTGGGGAA-3 ʼ  as a positive control for 
the RT-PCR analysis. PCR was conducted as described earlier. 
 
Complementation and survival assays in PrimPol-/- DT40 cells 
DT40 cells were cultured in RPMI1640 medium (Nakalai Tesque, Kyoto, Japan) 
supplemented with 10% heat inactivated fetal calf serum (FCS) (Biosera, France, 
lot No. 10011953), 1% chicken serum (Gibco BRL, Grand Island, HY, USA), 10-5 
M mercaptoethanol, 50U/ml penicillin and 50μg/ml streptomycin (Nakalai 
Tesque) at 39.5°. PrimPol-/- cells were complemented with transgene as 
previously described.13 Expression of PrimPol in PrimPol-/- cells was confirmed 
by western blot analysis using α-CCDC111 (N-13) antibody (Santa Cruz). We 
measured the amount of ATP in the cellular lysates to determine the number of 
surviving cells.49, 50 Cells were treated with each DNA damaging agent 
(camptothecin, ICRF193 and HU) in 1 ml of medium using 24-well plates and 
incubated at 39.5° C for 48 h. To analyze sensitivity to γ-rays, cells were 
irradiated using a 60Co γ-ray source and diluted to 104 cells /ml in 24-well plates 
and incubated at 39.5° C for 48 h. For UV light, 1 × 106 cells were suspended in 
0.5 ml of PBS (phosphate-buffered saline) containing 1% FCS in 6-well plates 
and irradiated with UVC (254 nm wavelength) and 10 µl of irradiated cells were 
transfer to 1 ml of medium using 24-well plates and incubated at 39.5° C for 48 h. 
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For MMS, 1 x 106 cells in PBS containing 1% FCS were exposed to MMS for 1 hr 
at 39.5° C and 10 µl of exposed cells were transferred to 1 ml of medium using 
24-well plates and incubated at 39.5° C for 48 h. Then, we transferred 100 µl of 
medium containing the cells to 96-well plates and measured the amount of ATP 
using CellTiter-Glo (Promega) according to the manufacturer's instructions. 
Luminescence was measured by Fluoroskan Ascent FL (Thermo Fisher 
Scientific Inc., Pittsburgh, PA). Camptothecin and ICRF193 interfere with 
Topoisomerse I and II, respectively, leading to strand breaks. HU inhibits 
ribonucleotide reductase and thereby prevents replication. MMS, cisplatin and 
UV induce chemical modifications in base, leading to replication stall at 
damaged bases. 
 
Measurement of sensitivity to CTNAs 
To measure the sensitivity to CTNAs, methylcellulose colony survival assays 
were performed as described previously.50, 51 ABC (Carbosynth, UK), ACV 
(Sigma, USA), and AZT (Sigma, USA) were mixed in methylcellulose medium. 
 
Flow-cytometric analysis of cell cycle progression 
To analyze cell-cycle progression, 1 × 106 cells were exposed for 10 min to 20 
µM 5-bromo-2ʼ-deoxyuridine (BrdUrd; Nacalai Tesque, Kyoto, Japan), then 
harvested and fixed with 70% ethanol. Fixed cells were incubated with 2 M HCl 
containing 0.5% Triton X-100, treated first with mouse anti-BrdUrd monoclonal 
antibody (BD PharMingen, San Diego, CA), then with FITC-conjugated 
anti-mouse IgG antibody (Southern Biotechnology Associates, Birmingham, AL). 
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Cells were resuspended in PBS containing 5 µg/ml propidium iodide (PI) for 
subsequent analysis using FACS Accuri (BD Biosciences). To measure the 
progression of the cell cycle, cells were synchronized at the G1 phase using 
centrifugal counterflow elutriation (Hitachi Industrial, Tokyo, Japan). The cell 
suspension (~5 × 107 cells) was loaded at a flow rate of 11 ml/min into an 
elutriation chamber running at 2,000 rpm. Cell synchrony was confirmed by 
FACS analysis. 
 
AID over-expression by retrovirus infection 
Wild-type, PrimPol -/-, Polη-/-/Polζ -/- and PrimPol-/-/Polη-/-/Polζ -/- cells were 
inoculated in 96-well plates to obtain single colonies. Single colonies were 
picked up and their genomic DNA extracted. After the DNA sequence of the 
V(D)J locus was analyzed, clones without any mutation or gene conversion in 
the V(D)J locus were obtained. AID overexpression by retrovirus infection was 
carried out as described previously 31, 52. The efficiency of infection was about 
70%, as assayed by GFP expression. Ig-gene conversion and hypermutation 
(events/Ig V segment/div) were calculated at dividing times 6.8, 7.0, 7.5 and 11.6 
h for wild-type, PrimPol -/-, Polη-/-/Polζ -/- and PrimPol-/-/Polη-/-/Polζ -/- cells, 
respectively. 
 
Analysis of Ig Vλ diversification 
Genomic DNA was extracted at 14 days post-infection. Using primers 
5ʼ-CAGGAGCTCGCGGGGCCGTCACTGATTGCCG-3ʼ at the lead Vλ intron 
position and 5ʼ-GCGCAAGCTTCCCCAGCCTGCCGCCAAGTCCAAG-3ʼ at the 
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back 3ʼ site of the JCλ intron, the rearranged Vλ segments were PCR amplified, 
cloned into the plasmid, and subjected to sequence analysis. To minimize 
PCR-introduced mutations, a high-fidelity polymerase, Prime Star GXL (Takara 
Bio), was used for amplification. The PCR products were cloned in a TOPO Zero 
Blunt vector (Invitrogen) and sequenced with the M13 forward (-20) primer. 
Sequencing analyses were done by Takara Bio. Sequence alignment with 
DNASIS-MAC v3.3 (HITACHI) allowed identification of changes from the 
parental sequence in each clone. The classification method used was as 
described previously.3, 5, 29, 31, 32 
 
Chromosomal Aberrations 
For our chromosomal aberration analysis of the DT40 cells, compound-treated 
wild-type and DNA repair-deficient clones were incubated at 39.5° C for 14.5 h. 
To arrest cells in the metaphase, 0.06% colcemid (GIBCO-BRL) was added 2.5 
h before harvest. Measurement of chromosome aberrations was performed as 
described previously.53-56 Briefly, cells were pelleted by centrifugation, 
resuspended in 7 ml of 75 mM KCl for 15 min at room temperature, and fixed in 2 
ml of a freshly prepared 3:1 mixture of methanol:acetic acid (Carnoyʼs solution). 
The pelleted cells were then resuspended in 7 ml of Carnoyʼs solution and 
pelleted and resuspended in 1 ml of Carnoyʼs solution, dropped onto clean glass 
slides, and air dried. Slides were stained with a 5% HARLECO Giemsa stain 
solution (Nacalai Tesque) for 20 min, rinsed with water and acetone, and dried. 
All chromosomes in each mitotic cell were scored at 1000× magnification. 
Chromosomal aberrations were classified as isochromatid or chromatid gaps, 
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breaks, and exchanges (fusions included triradial, quadriradial, ring, dicentric, 
and other) according to the ISCN system.57 
 
DNA repriming assays 
In vitro repriming assays were performed as described previously19 using DNA 
templates containing a single lesion and 5’ biotin modification annealed to 
3’-dideoxynucleotide primers (sequences listed in Supplementary Table 1). 
Oligonucloetides containing carbovir or acyclovir were chemically synthesized 
as described previously (Yamamoto et al. submitted). Briefly, PrimPol (1 µM) 
was incubated at 37°C for 15 mins in 20 µl reactions volumes containing 10mM 
Bis-Tris-Propane-HCl pH 7.0, 10mM MgCl2, 1mM DTT, 250 µM dNTPs or rNTPs, 
and 2.5 µM FAM dNTPs (dATP, dCTP, dUTP) (Jena-Biosciences). Reactions 
were quenched with binding-washing buffer (B-W) buffer (10 mM Tris-HCl pH 
7.5, 500 mM NaCl, 10 mM EDTA) and supplemented with ~20 µl streptavidin 
coated beads. Following DNA capture and washing with B-W buffer, beads were 
resuspended in 20 µL stop buffer (95% formamide solution with 0.25% 
bromophenol blue and xylene cyanol dyes) and heated to 95°C for 5 minutes. 
Reaction products were resolved on a 15% polyacrylamide / 7M urea gel for 90 
minutes at 21 watts and imaged using a FLA-5100 image reader (Fujifilm). 
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Figure legends 
Figure 1. PrimPol-deficient cells are sensitive to a wide range of DNA 
damaging agents  
PrimPol -/- cells exhibit hypersensitivity to various types of DNA damage. Cells 
with the indicated genotype were exposed to the indicated genotoxic agents. 
The dose of the genotoxic agent is displayed on the x-axis on a linear scale, 
while the percent fraction of surviving cells is displayed on the y-axis on a 
logarithmic scale. Error bars show the SD of the mean for three independent 
assays.  
 
Figure 2. PrimPol plays roles in damage tolerance independently of Polη 
and Polζ 
(A) Relative growth rate of cells plotted with indicated genotypes. Doubling time 
for the indicated cells was calculated. Error bars represent standard deviation 
from independent experiments (n=3). (B) Indicated cells were treated with 0 or 
100 nM of cisplatin for 16 hr. Representative cell-cycle distribution for the 
indicated genotypes. The top of the box, and the lower left, lower right, and 
left-most gates correspond to cells in the S, G1, and G2/M phases, and the 
sub-G1 fraction, respectively. The sub-G1 fraction represents dying and dead 
cells. The percentage of cells in each gate is indicated. (C) Percentage of the 
indicated cells in sub-G1 fraction and G2 phase fraction was indicated. Error bar 
represent standard deviation from independent experiments (n=3). Statistical 
significance was determined by a Studentʼs t-test and p-value was calculated. (*) 
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p<0.05 (D) Indicated cells were exposed to UV or cisplatin and sensitivities were 
indicated as in Fig. 1. 
 
Figure 3. PrimPol is dispensable for TLS past abasic sites during Ig Vλ 
hypermutation  
 (A) Ig Vλ segments isolated from indicated cells, clonally expanded for two 
weeks. Horizontal lines represent the rearranged Ig Vλ (450 bp), with 
hypermutation (lollipop shapes), gene conversion (horizontal bars), 
single-nucleotide substitutions that could be the result of hypermutation or gene 
conversion (vertical bars), and single-base deletion (boxes) determined as 
described previously.3, 5, 29, 31, 32 More than three clones were expanded for two 
weeks and analyzed for each data set. (B) Rate of gene conversion (GC) and 
hypermutation (PM) events are indicated with standard error. Statistical 
significance was determined by a Studentʼs t-test and p-value was calculated. 
(C) Pattern of point mutation in wild-type, PrimPol-/-, Polη-/-/Polζ-/- and 
PrimPol-/-/Polη-/-/Polζ-/- cells. Tables show the pattern of mutation in each line. 
 
Figure 4. PrimPolʼs primase activity is required for replication block 
tolerance. (A) Domain architecture of PrimPol. PrimPol is composed of an AEP 
polymerase and a Zn2+ finger domain. The PrimPol-Y89D mutation is located in 
the AEP polymerase. The PrimPol1-354 deletion mutant contains the 
polymerase domain but lacks the Zn2+ finger domain. A Zn2+ finger domain 
knockout mutant was generated by mutating the first conserved cysteine and 
histidine residues that coordinate Zn2+ (C419A and H426A, respectively). (B) 
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PrimPol -/- cells were complemented with variants of PrimPol and their in vivo 
expression was confirmed by western blot. Asterisks indicate non-specific bands. 
(C) Cells with the indicated genotype were exposed to the indicated genotoxic 
agents. The dose of the genotoxic agent is displayed on the x-axis on a linear 
scale, while the percent fraction of surviving cells is displayed on the y-axis on a 
logarithmic scale. Error bars show the SD of the mean for three independent 
assays. (D) Number of the chromosomal aberrations in 100 mitotic cells was 
presented. DT40 cells were exposed to cisplatin (150 nM) for 14.5 h and 
colcemid was added 2.5 h before harvest to accumulate a mitotic fraction. Error 
bars represent SD of the mean for three independent assays. Statistical 
significance was determined by a Studentʼs t-test and p-value was calculated. (*) 
p<0.05 (E) Sensitivity to cisplatin for indicated cells were indicated as in C. 
 
Figure 5. Role of PrimPolʼs primase activity to cellular tolerance to CTNAs 
(A) Cells with the indicated genotype were exposed to the indicated CTNAs. The 
dose of the genotoxic agent is displayed on the x-axis on a linear scale, while the 
percent fraction of surviving cells is displayed on the y-axis on a logarithmic 
scale. Error bars show the SD of the mean for three independent assays. (B) 
Sensitivity to ACV for indicated cells were indicated as in A. 
 
Figure 6. PrimPol catalyzes repriming downstream of 3ʼ incorporated 
CTNAs and templating abasic and thymine glycol lesions  
PrimPol (1μM) was incubated for 15 min at 37° C with dNTPs (250 μM), 
FAM-dNTPs (dATP, dCTP, dUTP) (2.5 μM), and mixed sequence 
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primer-templates (1 μM) (as shown in the schematic). Primers containing a 3ʼ 
dideoxynucleotide were annealed upstream of the lesion on templates 
containing a single Ap site (Ap) or thymine glycol (Tg) to allow us to assay for 
repriming, rather than TLS, activity. In the case of CTNAs a single CTNA 
(acyclovir (ACV) or carbovir (CBV)) was located at the 3ʼ end of the primer in 
place of the dideoxnucleotide. The length of primase reaction products extended 
to the end of the template allows analysis of the priming location by PrimPol; the 
near identical extension products produced in each case show close-coupled 
repriming by PrimPol downstream of the lesion or CTNA. Oligonucleotide 
nucleotide (Nt) length markers are shown in the left panel. Priming and 
extension are represented in the schematic as green and blue, respectively. “C” 
indicates the no enzyme control. “ND” indicates the non-damaged template 
without an annealed primer. 
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  cells	  was	  
calculated.	  Error	  bars	  represent	  standard	  devia/on	  from	  independent	  experiments	  (n=3).	  (B)	  Indicated	  cells	  were	  
treated	  with	  0	  or	  100	  nM	  of	  cispla/n	  for	  16	  hr.	  Representa/ve	  cell-­‐cycle	  distribu/on	  for	  the	  indicated	  genotypes.	  
The	  top	  of	  the	  box,	  and	  the	  lower	  leO,	  lower	  right,	  and	  leO-­‐most	  gates	  correspond	  to	  cells	  in	  the	  S,	  G1,	  and	  G2/M	  
phases,	  and	  the	  sub-­‐G1	  frac/on,	  respec/vely.	  The	  sub-­‐G1	  frac/on	  represents	  dying	  and	  dead	  cells.	  The	  percentage	  
of	  cells	  in	  each	  gate	  is	  indicated.	  (C)	  Percentage	  of	  the	  indicated	  cells	  in	  sub-­‐G1	  frac/on	  and	  G2	  phase	  frac/on	  was	  
indicated.	  Error	  bar	  represent	  standard	  devia/on	  from	  independent	  experiments	  (n=3).	  Sta/s/cal	  signiﬁcance	  was	  
determined	  by	  a	  Student’s	  t-­‐test	  and	  p-­‐value	  was	  calculated.	  (*)	  p<0.05	  (D)	  Indicated	  cells	  were	  exposed	  to	  UV	  or	  
cispla/n	  and	  sensi/vi/es	  were	  indicated	  as	  in	  Fig.	  1.	  	
Figure	  3.	  PrimPol	  is	  dispensable	  for	  TLS	  past	  abasic	  sites	  during	  Ig	  Vλ	  hypermuta6on	  	
	  (A)	  Ig	  Vλ	  segments	  isolated	  from	  indicated	  cells,	  clonally	  expanded	  for	  two	  weeks.	  Horizontal	  lines	  represent	  the	  
rearranged	  Ig	  Vλ	  (450	  bp),	  with	  hypermuta/on	  (lollipop	  shapes),	  gene	  conversion	  (horizontal	  bars),	  single-­‐
nucleo/de	  subs/tu/ons	  that	  could	  be	  the	  result	  of	  hypermuta/on	  or	  gene	  conversion	  (ver/cal	  bars),	  and	  single-­‐
base	  dele/on	  (boxes)	  determined	  as	  described	  previously.3,	  5,	  28,	  30,	  31	  More	  than	  three	  clones	  were	  expanded	  for	  
two	  weeks	  and	  analyzed	  for	  each	  data	  set.	  (B)	  Rate	  of	  gene	  conversion	  (GC)	  and	  hypermuta/on	  (PM)	  events	  are	  
indicated	  with	  standard	  error.	  Sta/s/cal	  signiﬁcance	  was	  determined	  by	  a	  Student’s	  t-­‐test	  and	  p-­‐value	  was	  
calculated.	  (C)	  PaFern	  of	  point	  muta/on	  in	  wild-­‐type,	  PrimPol-­‐/-­‐,	  Polη-­‐/-­‐/Polζ-­‐/-­‐	  and	  PrimPol-­‐/-­‐/Polη-­‐/-­‐/Polζ-­‐/-­‐	  cells.	  
Tables	  show	  the	  paFern	  of	  muta/on	  in	  each	  line.	
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Figure	  4.	  PrimPol’s	  primase	  ac6vity	  is	  required	  for	  replica6on	  block	  tolerance.	  (A)	  Domain	  architecture	  of	  PrimPol.	  
PrimPol	  is	  composed	  of	  an	  AEP	  polymerase	  and	  a	  Zn2+	  ﬁnger	  domain.	  The	  PrimPol-­‐Y89D	  muta/on	  is	  located	  in	  the	  
AEP	  polymerase.	  The	  PrimPol1-­‐354	  dele/on	  mutant	  contains	  the	  polymerase	  domain	  but	  lacks	  the	  Zn2+	  ﬁnger	  
domain.	  A	  Zn2+	  ﬁnger	  domain	  knockout	  mutant	  was	  generated	  by	  muta/ng	  the	  ﬁrst	  conserved	  cysteine	  and	  his/dine	  
residues	  that	  coordinate	  Zn2+	  (C419A	  and	  H426A,	  respec/vely).	  (B)	  PrimPol	  -­‐/-­‐	  cells	  were	  complemented	  with	  variants	  
of	  PrimPol	  and	  their	  in	  vivo	  expression	  was	  conﬁrmed	  by	  western	  blot.	  (C)	  Cells	  with	  the	  indicated	  genotype	  were	  
exposed	  to	  the	  indicated	  genotoxic	  agents.	  The	  dose	  of	  the	  genotoxic	  agent	  is	  displayed	  on	  the	  x-­‐axis	  on	  a	  linear	  
scale,	  while	  the	  percent	  frac/on	  of	  surviving	  cells	  is	  displayed	  on	  the	  y-­‐axis	  on	  a	  logarithmic	  scale.	  Error	  bars	  show	  the	  
SD	  of	  the	  mean	  for	  three	  independent	  assays.	  (D)	  Number	  of	  the	  chromosomal	  aberra/ons	  in	  100	  mito/c	  cells	  was	  
presented.	  DT40	  cells	  were	  exposed	  to	  cispla/n	  (150	  nM)	  for	  14.5	  h	  and	  colcemid	  was	  added	  2.5	  h	  before	  harvest	  to	  
accumulate	  a	  mito/c	  frac/on.	  Error	  bars	  represent	  SD	  of	  the	  mean	  for	  three	  independent	  assays.	  Sta/s/cal	  
signiﬁcance	  was	  determined	  by	  a	  Student’s	  t-­‐test	  and	  p-­‐value	  was	  calculated.	  (*)	  p<0.05	  (E)	  Sensi/vity	  to	  cispla/n	  for	  
indicated	  cells	  were	  indicated	  as	  in	  C.	
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Figure	  5.	  Role	  of	  PrimPol’s	  primase	  ac6vity	  to	  cellular	  tolerance	  to	  CTNAs	
(A)	  Cells	  with	  the	  indicated	  genotype	  were	  exposed	  to	  the	  indicated	  CTNAs.	  The	  dose	  of	  the	  
genotoxic	  agent	  is	  displayed	  on	  the	  x-­‐axis	  on	  a	  linear	  scale,	  while	  the	  percent	  frac/on	  of	  surviving	  
cells	  is	  displayed	  on	  the	  y-­‐axis	  on	  a	  logarithmic	  scale.	  Error	  bars	  show	  the	  SD	  of	  the	  mean	  for	  three	  
independent	  assays.	  (B)	  Sensi/vity	  to	  ACV	  for	  indicated	  cells	  were	  indicated	  as	  in	  A.	
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  Figure  6
Figure	  6.	  PrimPol	  catalyzes	  repriming	  downstream	  of	  3’	  incorporated	  CTNAs	  and	  templa6ng	  abasic	  
and	  thymine	  glycol	  lesions	  	
PrimPol	  (1μM)	  was	  incubated	  for	  15	  min	  at	  37°	  C	  with	  dNTPs	  (250	  μM),	  FAM-­‐dNTPs	  (dATP,	  dCTP,	  dUTP)	  
(2.5	  μM),	  and	  mixed	  sequence	  primer-­‐templates	  (1	  μM)	  (as	  shown	  in	  the	  schema/c).	  Primers	  
containing	  a	  3’	  dideoxynucleo/de	  were	  annealed	  upstream	  of	  the	  lesion	  on	  templates	  containing	  a	  
single	  Ap	  site	  (Ap)	  or	  thymine	  glycol	  (Tg).	  In	  the	  case	  of	  CTNAs	  a	  single	  CTNA	  (acyclovir	  (ACV)	  or	  carbovir	  
(CBV))	  was	  located	  at	  the	  3’	  end	  of	  the	  primer	  in	  place	  of	  the	  dideoxnucleo/de.	  The	  length	  of	  primase	  
reac/on	  products	  extended	  to	  the	  end	  of	  the	  template	  allows	  analysis	  of	  the	  priming	  loca/on	  by	  
PrimPol;	  the	  near	  iden/cal	  extension	  products	  produced	  in	  each	  case	  show	  close-­‐coupled	  repriming	  by	  
PrimPol	  downstream	  of	  the	  lesion	  or	  CTNA.	  Oligonucleo/de	  nucleo/de	  (Nt)	  length	  markers	  are	  shown	  
in	  the	  leO	  panel.	  Priming	  and	  extension	  are	  represented	  in	  the	  schema/c	  as	  green	  and	  blue,	  
respec/vely.	  “C”	  indicates	  the	  no	  enzyme	  control.	  “ND”	  indicates	  the	  non-­‐damaged	  template	  without	  
an	  annealed	  primer.	
	
